Jansen EGFR/MET dual-specific antibodies had positive results in the treatment of specific non-small cell lung cancer

Janssen, a unit of Johnson and Johnson, has released the latest results for its dual-specific antibody amivantamab, which is used to treat patients with metastasis or inexorable small cell lung cancer (NSCLC) inserted in the treatment of exosome 20 that carries a dermis growth factor (EGFR).
data were first presented as oral reports at the World Lung Cancer Congress (WCLC) 2020.
results showed that amivantamab achieved an objective remission rate of 40% and a disease control rate of 74%.
NSCLC accounts for 80%-85% of all lung cancers, with the main subsypes adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
most common drive mutation in NSCLC is the change in EGFR, a tyrosine kinase that supports cell growth and division.
EGFR mutations occur in 40%-50% of Asian patients.
the five-year survival rate of all patients treated with EGFR tyrosine kinase inhibitors was less than 20%, and the prognostic prognostics were particularly poor in NSCLC patients with EGFR exon 20 insertion mutations.
Amivantamab is an all-humanized EGFR/MET dual-specific antibody.
addition to blocking signaling mediated by EGFR and MET, it can also direct immune cells to target tumors that carry activation and resistance to EGFR/MET mutations and amplification.
it has been awarded a breakthrough fda degree for treating patients with EGFR exon 20 insertions.
amivantamab can kill NSCLC cells through a variety of mechanisms (Photo source: Resources 2) The data published this time include 81 NSCLC treated patients treated with Amivantamab monodrings in an open-label Phase 1 clinical trial called CHRYSALIS.
the results of the independent review of blindness, amivantamab achieved an objective mitigation rate of 40 per cent, including 3 complete remissions and 29 partial remissions.
mitigation time is persistent, with a medium mitigation duration of 11.1 months.
the medium non-progressed lifetime was 8.3 months and the medium total lifetime was 22.8 months.
" results further underscore the potential of amivantamab to treat patients with NSCLC who carry EGFR exon 20 insertion mutations.
"We are committed to harnessing our expertise to improve the diagnosis and treatment of lung cancer patients around the world and to bring innovative therapies to patients with limited treatment options," said Dr. Kiran Patel, Vice President of Clinical Development for Jansen's R and D solid tumors.
" References: New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Reed Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations. Retrieved January 29, 2021, from Yun et al., (2020). Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC. Cancer Discovery, DOI: 10.1158/2159-8290